Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SpePharm plans to launch MuGard in the rest of Europe over the coming 12 to 18 months
Subscribe to our email newsletter
Access Pharmaceuticals has announced that the company has received issue notifications from the US Patent and Trademark Office that two US patents relating to MuGard, the company’s approved oral rinse product for the management of mucositis will issue in June as US Patent numbers 7544348 and 7547433.
MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis.
Access has announced that MuGard was launched in Germany, Italy, UK, Greece and the Nordic countries by its European commercial partner, SpePharm. Under a license from Access Pharmaceuticals, SpePharm is responsible for manufacturing, regulatory approval and commercialization in the 27 countries of Europe. SpePharm plans to launch MuGard in the rest of Europe over the coming 12 to 18 months. The license agreement includes royalties on net sales to Access.
Phillip Wise, Vice President of Business Development at Access, said: SpePharm and Access are pleased with the commercial launch of MuGard in Europe, and while it is still in the early days, initial feedback has been positive.